Integer (US:ITGR) Globenewswire·2025-12-12 11:01Core Viewpoint - The Integer Holdings Corporation is facing a class action lawsuit for allegedly making false statements and failing to disclose critical information regarding its competitive position and sales performance in the electrophysiology market, leading to significant stock price declines [3][4]. Company Overview - Integer Holdings operates as a medical device contract development and manufacturing company [2]. Allegations of the Lawsuit - The lawsuit claims that Integer Holdings overstated its competitive position in the electrophysiology manufacturing market [3]. - It is alleged that the company experienced a deterioration in sales for two of its electrophysiology devices, contrary to its claims of strong customer demand [3]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its Cardio & Vascular segment [3]. Financial Performance and Guidance - On October 23, 2025, Integer Holdings lowered its full-year 2025 sales guidance, which was below analysts' expectations [4]. - The company projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for the full year of 2026 [4]. - Following the announcement, the stock price of Integer Holdings fell by more than 32% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Integer Holdings common stock during the class period to seek appointment as lead plaintiff in the lawsuit [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].